Soon Lee, MD
Ophthalmology · Oakland, CANPI 1952394553
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,800 of the $4,588 with a category attached, or 82.8%. Carl Zeiss Meditec, Inc. accounts for 82.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $3,765 and has fallen 98.7% since, to $47 in 2025.
Across 20 payments — averaging $229.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$4K
- Alcon$281
- Novartis$245
- Genentech USA, Inc.$114
- Amgen$75
- AbbVie$38
- plus $35 from 2 others
Across 4 payments — averaging $3431.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Carl Zeiss Meditec, Inc.$14K
What the payments were for
- Consulting fees$3,80083%
- Food & beverage$74416%
- Education$241%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 4 | $3,800 |
| Alcon | 2 | $281 |
| Novartis | 2 | $245 |
| Genentech USA, Inc. | 5 | $114 |
| Amgen(2 entities) | 3 | $75 |
| AbbVie | 2 | $38 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Regeneron | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARUS$300
- NGENUITY$281
- Constellation$281
How this compares
$4,588 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 77 | $4,476 |
| Methazolamide | 11 | $3,878 |
| Brimonidine Tartrate | 11 | $1,709 |
| Ketorolac Tromethamine | 39 | $686 |
| Latanoprost | 69 | $540 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $528 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 47 | $310 |
| Timolol Maleate | 15 | $149 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Oakland
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.